Douglas J. Manion - 01 Aug 2022 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACRS	Employee Stock Option (Right to Buy)	Award	$0	+217,800		$0.000000	217,800	01 Aug 2022	Common Stock	217,800	$13.62	Direct	F1
transaction	ACRS	Restricted Stock Units	Award	$0	+62,300		$0.000000	62,300	01 Aug 2022	Common Stock	62,300		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	Exercisable with respect to 25% of the shares subject to the option vesting in four equal annual installments beginning on August 1, 2023, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.
F2	Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
F3	The shares underlying these restricted stock units vest in four equal annual installments beginning on August 1, 2023, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.